Eikon Therapeutics appointed CP Chang as its new Chief Strategy Officer.

Eikon Therapeutics is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. We are passionate about novel therapeutics and share the belief that a better understanding of fundamental human disease biology can lead to better medicines. We are driven to go beyond incremental improvements. Instead, our goal is to introduce new therapies into clinical practice that will improve and extend life. Our clinical programs in oncology leverage immune response modulation and synthetic lethality to improve cancer therapy, while our discovery efforts are focused on identifying novel targets through application of single-molecule imaging to the study of cancer and neurological diseases. By applying machine learning algorithms to the very large imaging data sets that emerge from our imaging platforms, we can advance our programs towards our ultimate goal of discovering and developing better medicines. Eikon is seeking intellectually curious, passionate, and creative team members that are eager to apply their talents to empower interdisciplinary scientific exploration and ultimately create and develop novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions

Founded 2019